Last reviewed · How we verify
ketorolac 0.4%, bromfenac 0.09%
Ketorolac 0.4% and bromfenac 0.09% are marketed ophthalmic solutions developed by Innovative Medical, currently holding a position in the competitive landscape of anti-inflammatory eye treatments. The key composition patent, set to expire in 2028, provides a significant period of market exclusivity, enhancing the drug's competitive advantage. The primary risk lies in the potential for increased competition once the patent expires, which could impact revenue and market share.
At a glance
| Generic name | ketorolac 0.4%, bromfenac 0.09% |
|---|---|
| Sponsor | Innovative Medical |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase (PHASE4)
- Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects (PHASE4)
- Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ketorolac 0.4%, bromfenac 0.09% CI brief — competitive landscape report
- ketorolac 0.4%, bromfenac 0.09% updates RSS · CI watch RSS
- Innovative Medical portfolio CI